环状RNA作为卵巢癌生物标志物与治疗靶点
本文综述了上皮性卵巢癌(EOC)中组织和循环环状RNA(circRNA)作为诊断、预后及治疗反应生物标志物的证据,并讨论了在临床实验室实施circRNA检测所需的条件。血浆/血清中多种circRNA(如circBNC2等)具有诊断潜力(AUC典型范围0.79-0.95),可增强基于CA125和HE4的多标志物算法。但多数研究样本量小、缺乏外部验证,分析前处理和报告异质性显著,需强标准化和监管级验证才能常规应用。
要点
- 循环circRNA(如circBNC2等)诊断EOC的AUC典型范围0.79-0.95,可补充CA125/HE4。
- 临床落地需MIQE兼容的检测设计、分析前变量控制、标准化及外部质量评估。
- 现有证据多来自小队列且缺乏外部验证,分析前异质性大,尚不足以常规开展。
核心结论
- 循环circRNA作为EOC诊断标志物具潜力,但标准化与监管级验证不足,暂不能常规用于诊断、风险分层或治疗监测。
研究设计与样本
- 综述汇总组织和循环circRNA作为EOC诊断、预后及治疗反应标志物的证据,并讨论实验室实施挑战。
主要发现
- 血浆/血清中circBNC2、hsacirc0003972、hsacirc0007288和circN4BP2L2等circRNA具诊断潜力,AUC典型范围0.79-0.95。
- 这些circRNA可增强基于CA125和HE4的多标志物算法。
- 多数已发表研究队列小、缺乏外部验证,分析前处理与报告异质性显著。
关键数值与推荐
- 诊断潜力以AUC典型范围0.79-0.95表示(血浆/血清circRNA用于EOC)。
- 实验室实施需MIQE兼容的检测设计(检测back-splice junction)及样本特异分析前变量控制(溶血、凝血时间、外泌体分离流程)。
- 需标准化液体活检归一化策略、分析验证、参考区间/决策限及外部质量评估。
临床怎么用
- 目前circRNA检测不宜替代CA125/HE4用于EOC早期诊断或附件肿块分诊,仅可研究性探索。
- 临床实验室引入前应建立MIQE兼容方法、控制分析前变量并参与外部质量评估。
局限性
- 多数研究样本量小且缺乏外部验证。
- 分析前处理与报告异质性显著。
- 缺乏强标准化和监管级验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current laboratory diagnostic tools for epithelial ovarian cancer (EOC) primarily rely on cancer antigen 125 (CA125) and human epididymis protein 4 (HE4). However, their effectiveness is suboptimal for early disease diagnosis and triage of adnexal masses. The evidence reviewed on the topic of tissue and circulating circular RNAs (circRNAs) as diagnostic, prognostic, and treatment-response biomarkers in EOC and what is needed to implement circRNA assays in clinical laboratory practice are summarized herein. Several circRNAs identified in plasma/serum (such as circBNC2, hsacirc0003972, hsacirc0007288, and circN4BP2L2) have diagnostic potential (area under the receiver operating characteristic curve [AUC] between the typical range of 0.79-0.95) and can be used to enhance multimarker algorithms with CA125 and HE4. In addition to biomarker performance, we are interested in laboratory medicine challenges that can define clinical usability, such as Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE)-compatible assay design to detect back-splice junction, specimen-specific pre-analytical variables (e.g., hemolysis, clotting time, and exosome isolation workflows), normalization strategies of liquid biopsy, analytical validation, reference intervals/decision limits, and external quality assessment. Although published accuracies are encouraging, the majority of studies have small cohorts and lack external validation, and preanalytical handling and reporting heterogeneity are significant. Thus, strong standardization and regulatory level validation are necessary for circRNA testing to be established as a routine EOC diagnosis, risk stratification, or treatment monitoring tool.
引用
- Porwal O, Visht S, Muhammed RA, et al. Circular RNAs as biomarkers and targets in ovarian cancer. Clin Chim Acta. 2025. PMID: 41443567. doi:10.1016/j.cca.2025.120802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。